Establishments of the gastrointestinal surgery model in type 2 diabetes mellitus rats

Abstract

Abstract: AIM: To establish the gastrointestinal surgery model in type 2 diabetes mellitus rats.METHODS: 60 SPF-class male Sprague-Dawley(SD) rats were used. The rats were given a high-fat-sugar diet for 8 wk, followed with an intraperitoneal injection of streptozotocin (40mg/kg). 1 week after get success model, 24 rats from success model were randomly divided into two groups : duodenal jejunal bypass group(DJB, n=12),Roux-en-Y gastric bypass group(RYGB, n=12).RESULTS: 8 weeks after surgery,surviving rats in each group were ten, the overall survival rate of rats reached 83.3%.CONCLUSION: The animal model of type 2 diabetes to be given gastrointestinal operation as the treatment is feasible,which means can be used in long-term observation of foundation research and evaluation the effectiveness of clinical work.

Key words: Gastrointestinal surgery, Type 2 diabetes mellitus, Duodenal jejuna bypass, Roux-en-Y gastric bypass

CLC Number:

R965.2

XIA Ya-bin, ZHENG Cheng-zhu. Establishments of the gastrointestinal surgery model in type 2 diabetes mellitus rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 888-891.

References

[1] 何银辉, 徐海燕, 孙霞,等.2型糖尿病合理用药策略[J]. 中国临床药理学与治疗学, 2011, 27(7): 837-840.
[2] Rubino F,R'bibo SL,del Genio F,et al. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus[J]. Nat Rev Endocrinol,2010,6(2):102-109.
[3] Adams TD,Gress RE,Smith SC,et al. Long-term mortality after gastric bypass surgery[J]. N Engl J Med,2007,357(8):753-761.
[4] Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis[J].JAMA,2004,292(14):1724-1737.
[5] Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis[J]. Surgery,2007,142(4): 621-632.
[6] Sjöström L,Lindroos AK,Peltonen M,et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery[J].N Engl J Med, 2004, 351(26): 2683- 2693.
[7] Sjöström L,Gummesson A,Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial[J]. Lancet Oncol,2009,10(7):653-662.
[8] Srinivasan K,Viswanad B,Asrat L,et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and Pharmacological screening[J].. Pharmacol Res,2005,52(4):313-320.
[9] 郭啸华,刘志红,李恒等.实验性2型糖尿病大鼠模型的建立[J].肾脏病与透析肾移植杂志,2000,9(4):351-355.
[10] Han LO, Zhou LH, Cheng SJ, et al.Key details of the duodenal-jejunal bypass in type 2 diabetes mellitus rats[J].World J Gastroenterol,2011,17(45): 5021-5027.
[11] Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease[J]. Ann Surg, 2004, 239(l):l-11.
[12] Rubino F, Forgione A, Cummings DE,et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes[J]. Ann Surg,2006,244(5):741-749.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[7]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[8]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[9]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[10]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[11]	LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525.
[12]	NI Yingqun, XIE Fengtao, FANG Zhaohui. Danzhijiangtang capsule protects vasculopathy of T2DM: an evaluation based on the expression of Wnt/β-catenin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 531-537.
[13]	WANG Chanyue, WANG Ye, ZHANG Peipei, CHEN Mingyue, YANG Hao, ZHU Manli, LI Linlin. Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1321-1325.
[14]	KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409.
[15]	DONG Chao, WANG Tao, ZHOU Dongmei, WANG Ya, WANG Laicheng, LV Dongmei. Investigation and analysis of antidiabetic agents therapy in inpatients with type 2 diabetes mellitus in our hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 87-91.